Man Group’s Aquestive Therapeutics AQST Stock Holding History

Man Group’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Buy	+351,700	New	+$1.48M	﹤0.01%	1705
2026 Q1	–	Sell	-29,213	Closed	-$189K	–	2380
2025 Q4	$189K	Buy	+29,213	New	+$182K	﹤0.01%	2132
2024 Q3	–	Sell	-12,653	Closed	-$32.9K	–	1959
2024 Q2	$32.9K	Sell	12,653 -209,433	-94%	-$700K	﹤0.01%	1987
2024 Q1	$946K	Buy	+222,086	New	+$739K	﹤0.01%	1562
2023 Q3	–	Sell	-128,547	Closed	-$221K	–	1855
2023 Q2	$212K	Buy	+128,547	New	+$233K	﹤0.01%	1809
2023 Q1	–	Sell	-89,900	Closed	-$81.1K	–	2064
2022 Q4	$81.1K	Hold	89,900	–	–	﹤0.01%	1932
2022 Q3	$105K	Buy	+89,900	New	+$102K	﹤0.01%	1846
2022 Q2	–	Sell	-89,900	Closed	-$120K	–	1945
2022 Q1	$235K	Buy	89,900 +71,383	+385%	+$208K	﹤0.01%	1871
2021 Q4	$72K	Buy	+18,517	New	+$92.9K	﹤0.01%	1895

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Man Group's AQST Position: Q2 2026 in Review

Man Group opened a new position in Aquestive Therapeutics (AQST) in Q2 2026: 351,700 shares worth $1.46M. The stake represents ﹤0.01% of the portfolio and ranks #1705 among its holdings. This is a return to the name: Man Group previously reported a position in AQST as recently as Q4 2025.

Man Group first reported a position in AQST in Q4 2021 and has held it in 9 quarters since. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Man Group held 351,700 shares of Aquestive Therapeutics worth $1.46M as of Q2 2026.
Aquestive Therapeutics was a new Man Group position in Q2 2026.
Aquestive Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1705 holding.
Man Group first reported a position in Aquestive Therapeutics in Q4 2021 and has held it in 9 quarters since.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.